Overexpression of the receptor tyrosine kinase HER2/neu (ErbB2) in breast cancer, led to increased HIF-1α expression, increased ERK and Akt activities, reduced Bim expression and resistance to anoikis [224]. Here, ERBB2 is linked to breast carcinoma.